Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Early diagnosis leads King Charles to scale back cancer treatment in the new year - 2Step by step instructions to Explore Assessment Ramifications of Disc Rates
- 3Police break up illegal chicken slaughter in Germany
- 4Tata Motors, BMW among automakers set to raise prices in India
- 5West Palm Beach Shorecrest, renderings of downtown waterfront condo
- Flu cases skyrocket in US. See cases, where people got sick.
- Manual for Conservative SUVs For Seniors
- U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- Man threatens attack on German high-speed train, 12 lightly injured
- Unwinding History's Secrets: Looking for the Response to Antiquated Human advancements
- Manual for Tracking down One of a kind Store Inns
- Apartment Turned Into Nightmare 'Ice Castle' After Tenant Shut Off Heat Causing Pipes to Burst: VIDEO
- Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak
- Understanding Preschool Projects: An Extensive Aide
